Vector BioMed Launches in Maryland with Gene Therapy Industry Veteran at Helm to Address the Vector Supply Bottleneck with End-to-End Solutions Platform

Published on : Published by : Chris Frew

Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
NEWS PROVIDED BY
Vector BioMed
Jan 31, 2023, 07:30 ET
SHARE THIS ARTICLE
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…

Despite Strong 2021 Performance Headwinds Remain for Biosimilars Uptake

Published on : Published by : Steven Surdez

Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.

“There’s Gold in Them Thar Hills!” – VC Funding Floods BioHealth Capital Region in 2021

Photo of gold bars
Published on : Published by : Alex Keown

In the third quarter of 2021 alone, more than $400 million of private capital was invested in Maryland businesses. The money went to more than 34 different companies, according to data compiled by PitchBook. The deals brought the state to about $1.6 billion in funding for the first three-fourths of the year and placed Maryland on track to bring in about $2 billion worth of VC funding for the year. That was a significant jump over 2020, when Maryland saw about $1.26 billion in VC funding. For the industry at large in 2020, VC activity in biotechs grew by 45% to $36.6 billion.